LID

Velvet, FuturaSun's first range of heterojunction products, is here to stay

Retrieved on: 
Thursday, February 23, 2023
PERC, Heterojunction, Boron, Weather, Bos, Phosphorus, Silicon, PV, Cell, WP, LID, HJT, Human, TCO, N-type calcium channel, LCOE, Renewable energy, Velvet

This glass-glass bifacial module is based on N-type heterojunction (HJT) bifacial solar cells.

Key Points: 
  • This glass-glass bifacial module is based on N-type heterojunction (HJT) bifacial solar cells.
  • Heterojunction technology combines crystalline silicon with silicon based thin film to absorb more energy and reach higher performance (higher than the PERC modules).
  • In addition, the layers of Transparent Conductive Oxide (TCO) make the cell more uniform, enhancing the module's aesthetics from both sides.
  • The Velvet Pro range features a glass-glass structure with 120 or 144 HJT MMB half-cut cells (166 mm – M6).

Velvet, FuturaSun's first range of heterojunction products, is here to stay

Retrieved on: 
Thursday, February 23, 2023
PERC, Heterojunction, Boron, Weather, Bos, Phosphorus, Silicon, PV, Cell, WP, LID, HJT, Human, TCO, N-type calcium channel, LCOE, Renewable energy, Velvet

This glass-glass bifacial module is based on N-type heterojunction (HJT) bifacial solar cells.

Key Points: 
  • This glass-glass bifacial module is based on N-type heterojunction (HJT) bifacial solar cells.
  • Heterojunction technology combines crystalline silicon with silicon based thin film to absorb more energy and reach higher performance (higher than the PERC modules).
  • In addition, the layers of Transparent Conductive Oxide (TCO) make the cell more uniform, enhancing the module's aesthetics from both sides.
  • The Velvet Pro range features a glass-glass structure with 120 or 144 HJT MMB half-cut cells (166 mm – M6).

InventHelp Inventor Develops Sanitary Cover for Beverage Glass Rims (CSK-337)

Retrieved on: 
Wednesday, February 15, 2023
Sale, LID, Mouth, Bacteria, Eating, Multimedia, Safety, LIP, Virus, Canning

My design enables you to enjoy your drink in a safe and sanitary manner."

Key Points: 
  • My design enables you to enjoy your drink in a safe and sanitary manner."
  • The patent-pending invention provides an effective cover for the rim of a beverage glass.
  • As a result, it increases sanitary conditions and safety and it provides added peace of mind.
  • The original design was submitted to the Columbia sales office of InventHelp.

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

Retrieved on: 
Wednesday, February 1, 2023
Diamond, Ketamine, Food, Safety, Fast track (FDA), Fast Track, Trial of the century, Pain, Type, Motor disorder, LID, Accelerated approval (FDA), Depression, Patient, NDMA, Collection, CSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Patent, Movement, Hypertension, Levodopa-induced dyskinesia, Dyskinesia, USD, Priority review, Pharmaceutical industry, Bookkeeping

In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™.

Key Points: 
  • In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™.
  • The goal date for the FDA in providing its written responses is March 20, 2023.
  • Summary results of the study:
    Enrolled subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr.
  • Clinical programs conducted under Fast Track Designation may be eligible for Accelerated Approval and Priority Review of new drug applications if relevant criteria are met.

LightBox and First Street Foundation Expand Partnership Creating a Unique Ability to Price and Evaluate Climate Risk

Retrieved on: 
Tuesday, January 10, 2023
API, Flood, LID, Risk, Wildfire, Partnership, Climate, Research, Lightbox, First Street, Risk management

Through the partnership, First Street Foundation’s Risk Factor tool will be incorporated into LightBox products, making it easier to identify and measure climate risks ranging from floods and wildfires to extreme heat.

Key Points: 
  • Through the partnership, First Street Foundation’s Risk Factor tool will be incorporated into LightBox products, making it easier to identify and measure climate risks ranging from floods and wildfires to extreme heat.
  • The First Street Foundation’s peer reviewed, climate adjusted flood, wildfire and extreme heat models compute risk at the individual property level and incorporate the best available climate science to understand how risk is changing over time.
  • It leverages LightBox’s Nationwide Location Fabric in its estimation of climate impacts specific to each property in the United States under different climate scenarios.
  • “The data provided by LightBox is a critical component of the First Street Foundation flood, wildfire and extreme heat risk models, allowing us to analyze the specific climate risk facing each property in the country, and how it’s changing over time,” said Matthew Eby, CEO of First Street Foundation.

Canadian Solar to Start Mass Production of TOPCon Modules with Power Output up to 690W

Retrieved on: 
Thursday, December 15, 2022
BOS, Electricity, Morgan Solar Inc, Solar, LID, PERC, Harbor, Temperature, ESG, Topcon, PV, Uncertainty, COVID-19, Solar energy, Annual report, Failure, LCOE, Climate change, Pressure, Renewable energy, Canadian Solar

GUELPH, ON, Dec. 15, 2022 /PRNewswire/ -- Canadian Solar Inc. (the "Company", or "Canadian Solar") (NASDAQ: CSIQ), today announced that its majority-owned subsidiary CSI Solar Co., Ltd. will start mass production of high efficiency N-type TOPCon (Tunnel Oxide Passivated Contact) solar modules in the first quarter of 2023.

Key Points: 
  • GUELPH, ON, Dec. 15, 2022 /PRNewswire/ -- Canadian Solar Inc. (the "Company", or "Canadian Solar") (NASDAQ: CSIQ), today announced that its majority-owned subsidiary CSI Solar Co., Ltd. will start mass production of high efficiency N-type TOPCon (Tunnel Oxide Passivated Contact) solar modules in the first quarter of 2023.
  • Canadian Solar will provide a diversified portfolio of the TOPCon products to meet the needs for utility-scale, commercial and residential markets.
  • Canadian Solar will deliver the 182mm cell based TOPCon modules in the first quarter of 2023 and will start mass production of the 210mm cell based TOPCon modules in the second quarter of 2023.
  • Dr. Shawn Qu , Chairman and CEO of Canadian Solarcommented,"We arepleased to start delivering our cutting-edge N-type TOPCon modules early next year.

BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients

Retrieved on: 
Tuesday, November 29, 2022
Pathology, Neuroinflammation, ADAS, Neurodegeneration, DSMB, TNF, Hand, CSF, Liver disease, Cognition, Insulin resistance, Degenerative disease, AD, Patient, Cirrhosis, L-DOPA, NF-κB, Inflammation, Microglia, AE, Dyskinesia, Fast track (FDA), 8-K, PD, Alzheimer's disease, ALS, LID, Trial of the century, ERK, Data analysis, Oxidative stress, Survival, Neuron, Ascites, Safety, Probability, Pharmaceutical industry, Medicine

The NM101 trial is a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028).

Key Points: 
  • The NM101 trial is a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028).
  • The NM101 trial protocol specified enrolling at least 316 patients equally randomized to treatment and placebo arms.
  • The pace of enrollment increased dramatically in recent months, creating a situation where the Company finished enrolling all 316 patients before50% of enrolled patients had completed the study.
  • A Phase 2 study of NE3107 in Parkinsons disease (NCT05083260) is fully enrolled and expects to have topline data readout in December 2022.

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience

Retrieved on: 
Monday, November 14, 2022
Diamond, FDA, Substance, University, CSE, Constipation, LID, Dysautonomia, Brain, Ketamine, Patent, Dyskinesia, Drug combination, L-DOPA, Rigidity, Levodopa-induced dyskinesia, USD, Motor disorder, United States Patent and Trademark Office, Neurogenic bladder dysfunction, Depression, NDMA, Mental health, Pain, Psychiatry, Tremor, Central nervous system, Neuron, Substantia nigra, Hypertension, Dopamine, Hypokinesia, OTCQB, Orthostatic hypotension, Patient, Movement, Pharmaceutical industry

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that a poster presentation of the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at Neuroscience 2022 by the Society for Neuroscience being held November 12-16, 2022, at the San Diego Convention Center in San Diego, California. In addition, the Company has engaged the FDA to establish the next steps for a planned Phase 3 clinical study to allow for the Company’s proprietary ketamine intravenous product, KETARX™, approval for Parkinson’s disease under the 505(b)(2) regulatory pathway.

Key Points: 
  • A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
  • Parkinsons disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide.
  • The possible therapeutic effect of low-dose ketamine on levodopa-induced dyskinesia was noted in a retrospective analysis of Parkinsons disease patients who received ketamine for pain relief.
  • There is currently no cure for Parkinsons disease, although some drug combinations are used to treat the disease symptoms.

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Retrieved on: 
Thursday, November 17, 2022
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Neuropharmacology, Cell, FDA, Fast Track, Glycine, MDD, LID, Anxiety, PH94B, Brain, Central nervous system disease, Neuropathic pain, Faculty of Pharmacy, University of Lisbon, Patent, NMDA, Université Laval, Dyskinesia, PH10, NMDAR, Parkinson's disease, Patient, L-DOPA, Dissociative, Quality of life, PD, CNS, Research, Faculty, MPTP, CHU, Depression, Risk, Annual report, Therapy, Central nervous system, Neuron, Probenecid, Ketamine, Pharmaceutical industry, Risk management, Pharmacy

While L-Dopa remains the most effective pharmacotherapy for Parkinsons disease, the occurrence of LID is difficult to manage and drastically interferes with Parkinsons patients quality of life.

Key Points: 
  • While L-Dopa remains the most effective pharmacotherapy for Parkinsons disease, the occurrence of LID is difficult to manage and drastically interferes with Parkinsons patients quality of life.
  • This preclinical study showed that AV-101 reduced LID with no adverse effects of treatment, stated Shawn Singh, Chief Executive Officer of Vistagen.
  • Dr. Di Paolo has been at the forefront of research in neuropharmacology and treatments for Parkinsons disease for decades.
  • MPTP is a neurotoxin that kills dopaminergic neurons in the striatum, producing motor symptoms similar to those of PD.

Low Impact Development Technologies, LLC Receives Investment from Ember Infrastructure

Retrieved on: 
Tuesday, November 1, 2022
Water quality, Goal, Growth, Board of directors, Knowledge, Water, Efficiency, Board, LLC, Society, Industry, City, Agriculture, SWC, PPCP, Ageing, Safety, Maintenance, Carbon, American Society of Civil Engineers, Quality of life, Water pollution, Solution, Low-impact development (U.S. and Canada), LID, Sewage, Tunnel, Renewable energy, Ember

PORTLAND, Maine, Nov. 1, 2022 /PRNewswire/ -- Stormwater solutions provider Low Impact Development Technologies, LLC ("LID Tech") announced today it has received an investment from Ember Infrastructure ("Ember") to meet growing demand for its suite of green infrastructure products and services that enhance stormwater management in ways that reduce runoff and flooding while improving water quality, safety, and quality of life in urban and ultra-urban areas. 

Key Points: 
  • Ember invests in Low Impact Development Technologies to scale stormwater management solutions.
  • LID Tech also owns Stormwater Compliance, LLC ("SWC"), a full-service post-construction stormwater infrastructure inspection and maintenance business servicing a variety of commercial & industrial customers across the full spectrum of traditional stormwater systems and green infrastructure.
  • "Ember is proud to be partnering with the deeply experienced and innovative team at Low Impact Development Technologies," said Caleb Powers, Principal at Ember, who will join the company's Board of Directors.
  • Founded in 2006, Stormwater Compliance, LLC (SWC) inspects and services all types of traditional stormwater systems and green infrastructure.